logo BDSP

Base documentaire

  1. Second solid malignancies after combined modality therapy for Hodgkin's disease.

    Article - En anglais


    To determine the actuarial incidence (Al) and relative risk (RR) of second solid malignancies (SSM ; solid tumors and non-Hodgkin's lymphoma) in patients with Hodgkin's disease who were treated with chemotherapy and adjuvant, low-dose radiation (combined modality therapy ; CMT).

    Patients and Methods 

    From 1969 to 1983,102 patients with previously untreated advanced Hodgkin's disease (group A) and 81 patients with recurrent disease after radiation (group B) were treated with CMT.


    Nearly half of the patients entering remission were observed for greater than 15 years.

    At 20 years, the Al for SSM was 12% in group A versus 41% in group B (P=009).

    The overall RR for developing a ST in group A was 1.88 (not significant) versus 8.84 in group B (95% confidence interval, 5.3 to 15.4).

    The difference in the RR between groups A and B was significant (P<. 001).


    Previously untreated patients with advanced disease who were treated with CMT (group A) had a modest but not significant increase in the RR of ST ; however, patients treated with CMT for recurrent disease (group B) had a highly significant increase in the RR of ST.

    Possible explanations for the increase in ST in group B include more cumulative radiation or a greater carcinogenic effect of chemotherapy in previously irradiated patients, but it also is possible that the increase is due to a longer follow-up time.

    J Clin Oncol 13 : 2016-2022. 1995 by American Society of Clinical Oncology.

    Mots-clés Pascal : Hodgkin maladie, Homme, Chimiothérapie, Radiothérapie, Traitement associé, Toxicité, Long terme, Second cancer, Incidence, Facteur risque, Epidémiologie, Hémopathie maligne, Lymphoprolifératif syndrome, Lymphome, Tumeur maligne

    Mots-clés Pascal anglais : Hodgkin disease, Human, Chemotherapy, Radiotherapy, Combined treatment, Toxicity, Long term, Second cancer, Incidence, Risk factor, Epidemiology, Malignant hemopathy, Lymphoproliferative syndrome, Lymphoma, Malignant tumor

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0462675

    Code Inist : 002B19B. Création : 01/03/1996.